MAD2L1 and neoplasm: In contrast, MAD2L1 was strongly expressed in the nucleus and cytoplasm of most iCCA samples (68/82, 82.3%), while no MAD2L1 immunolabeling could be observed in the remaining 14 tumor specimens (Fig. 8).